Order Article Reprints

Ling SF, Ogungbenro K, Darwich AS, Ariff ABM, Nair N, Bluett J, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, et al. Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. Pharmaceutics. 2024; 16(6):702. https://doi.org/10.3390/pharmaceutics16060702

Ling, Stephanie F., Kayode Ogungbenro, Adam S. Darwich, Amirah Binti Mohammad Ariff, Nisha Nair, James Bluett, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, and et al. 2024. "Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis" Pharmaceutics 16, no. 6: 702. https://doi.org/10.3390/pharmaceutics16060702

Ling, S. F., Ogungbenro, K., Darwich, A. S., Ariff, A. B. M., Nair, N., Bluett, J., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A., & Plant, D. (2024). Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. Pharmaceutics, 16(6), 702. https://doi.org/10.3390/pharmaceutics16060702